PRF Technologies (PRFX) Change in Account Payables (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Change in Account Payables of -$761000.0 for Q2 2024, down 1327.42% year-on-year from $62000.0 in Q3 2023, and down 189.01% on a QoQ basis from $855000.0 in Q1 2024.
PRF Technologies (PRFX) Change in Account Payables (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Change in Account Payables for 5 consecutive years, with -$761000.0 the latest figure, recorded in Q2 2024.
- Quarterly Change in Account Payables fell 1327.42% year-over-year to -$761000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$30000.0 (down 105.41% YoY) and the FY2024 annual result came in at $91000.0, up 78.43% from the prior year.
- Change in Account Payables declined to -$761000.0 in Q2 2024 per PRFX's latest filing, from $855000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for PRFX reached as high as $855000.0 in Q1 2024 and fell as low as -$761000.0 in Q2 2024.
- A 5-year average of $60529.4 and a median of $62000.0 in 2023 frame the typical range for Change in Account Payables.
- The largest YoY upside for Change in Account Payables was 656.64% in 2024 against a maximum downside of 1327.42% in 2024.
- Year by year, Change in Account Payables stood at $172000.0 in 2020, then dropped by 1.16% to $170000.0 in 2021, then surged by 178.82% to $474000.0 in 2022, then slumped by 84.39% to $74000.0 in 2023, then slumped by 1128.38% to -$761000.0 in 2024.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$761000.0, $855000.0, and $74000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -761,000.00 |
| Jun 30, 2024 | -761,000.00 |
| Mar 31, 2024 | 855,000.00 |
| Mar 31, 2024 | 855,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | -198,000.00 |
| Sep 30, 2023 | -198,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Sep 30, 2022 | 474,000.00 |
| Sep 30, 2022 | 474,000.00 |
| Jun 30, 2022 | -94,000.00 |
| Jun 30, 2022 | -94,000.00 |
| Mar 31, 2022 | -186,000.00 |
| Mar 31, 2022 | -186,000.00 |
| Dec 31, 2021 | 170,000.00 |
| Dec 31, 2021 | 170,000.00 |